Invex Therapeutics

(ASX) IXC

Current Price$0.13

Market Cap$9.77M

Since IPO (2019)-53%

5 Year-32%

1 Year+60%

1 Month+30%

Invex Therapeutics Financials at a Glance

Market Cap

$9.77M

Revenue (TTM)

$1.44M

Net Income (TTM)

$722.02K

EPS (TTM)

$-0.01

P/E Ratio

-11.71

Dividend

$0.00

Beta (Volatility)

0.33 (Low)

Dividend

$0.00

Beta (Volatility)

0.33 (Low)

Price

$0.13

Volume

Open

$0.13

Price

$0.13

Volume

Open

$0.13

Previous Close

$0.13

Daily Range

$0.13 - $0.13

52-Week Range

$0.07 - $0.18

Dividend

$0.00

Beta (Volatility)

0.33 (Low)

Price

$0.13

Volume

Open

$0.13

Previous Close

$0.13

Daily Range

$0.13 - $0.13

52-Week Range

$0.07 - $0.18

IXC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Invex Therapeutics

Industry

Pharmaceuticals

Sector

Health Care

Website

www.invextherapeutics.com

Headquarters

Perth, WA 6008, AU

IXC Financials

Key Financial Metrics (TTM)

Gross Margin

100%

Operating Margin

-5%

Net Income Margin

-4%

Return on Equity

-17%

Return on Capital

-24%

Return on Assets

-18%

Earnings Yield

-8.54%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$9.77M

Shares Outstanding

75.15M

Volume

Avg. Volume

20.95K

Financials (TTM)

Gross Profit

$229.08K

Operating Income

$709.30K

EBITDA

$0.00

Operating Cash Flow

$652.57K

Capital Expenditure

$0.00

Free Cash Flow

$652.57K

Cash & ST Invst.

$5.38M

Total Debt

$0.00

Invex Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$9.77M

N/A

Market Cap/Employee

$2.44M

N/A

Employees

N/A

Net Income

$715.58K

+66.1%

EBITDA

$843.02K

-323.8%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Net Cash

$4.60M

-25.3%

Accounts Receivable

$128.00K

-0.5%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-17.70%

N/A

Return on Invested Capital

-23.76%

N/A

Free Cash Flow

$410.96K

+86.1%

Operating Cash Flow

$410.96K

+86.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

BGT.AXBio-Gene Technology Limited

BGT.AXBio-Gene Technology Limited$0.04+0.00%

ICR.AXIntelicare Holdings Limited

ICR.AXIntelicare Holdings Limited$0.02-4.00%

CHM.AXChimeric Therapeutics Limited

CHM.AXChimeric Therapeutics Limited$0.17-17.50%

VBS.AXVectus Biosystems Limited

VBS.AXVectus Biosystems Limited$0.11-8.33%

PER.AXPercheron Therapeutics Limited

PER.AXPercheron Therapeutics Limited$0.01+11.11%

BIT.AXBiotron Limited

BIT.AXBiotron Limited$0.00+20.00%

ACR.AXAcrux Limited

ACR.AXAcrux Limited$0.01+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$13.30+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.07+0.05%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.70+0.01%

SOFISoFi Technologies

SOFISoFi Technologies$16.43+0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$65.30+0.03%

NIONio

NIONio$5.91-0.08%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$50.22-0.03%

Questions About IXC

What is the current price of Invex Therapeutics?

Invex Therapeutics is trading at A$0.13 per share.

What is the 52-week range for Invex Therapeutics?

Over the past 52 weeks, Invex Therapeutics has traded between A$0.08 and A$0.18.

How much debt does Invex Therapeutics have?

As of the most recent reporting period, Invex Therapeutics reported total debt of N/A.

How much cash does Invex Therapeutics have on hand?

Invex Therapeutics reported $5.38M in cash and cash equivalents in its most recent financial results.

What is Invex Therapeutics’s dividend yield?

Invex Therapeutics does not currently have a dividend yield.

Invex Therapeutics

Invex Therapeutics Financials at a Glance

IXC News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Invex Therapeutics

IXC Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Invex Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IXC

What is the current price of Invex Therapeutics?

What is the 52-week range for Invex Therapeutics?

How much debt does Invex Therapeutics have?

How much cash does Invex Therapeutics have on hand?

What is Invex Therapeutics’s dividend yield?

Premium Investing Services